25th May 2018 08:19
LONDON (Alliance News) - AstraZeneca PLC on Friday said its biologics research arm MedImmune got positive overall survival results from the Phase III PACIFIC trial of Imfinzi drug in patients with unresectable Stage III non-small cell lung cancer.
The pharmaceutical firm said planned interim analysis met its second of two primary endpoints after demonstrating improvements in patients receiving Imfinzi compared to a placebo.
In May last year, AstraZeneca said that the PACIFIC trial met its first primary endpoint by showing a median improvement of 11.2 months versus placebo.
Currently, Imfinzi is approved for use in the US and Canada. The company expects the drug use expansion to the EU and Japan in the second half of 2018.
"The readout of positive overall survival data at the interim analysis of the PACIFIC trial provides additional compelling evidence of the clinical benefit that Imfinzi can offer patients in this earlier stage of lung cancer," said Executive Vice President Sean Bohen.
Shares in AstraZeneca were trading 0.5% higher at 5,454.00 pence each early on Friday.
Related Shares:
Astrazeneca